CITR News & Events

CitroTech issued a letter to Company shareholders. "As we reflect on 2025, we are pleased to report that CitroTech is entering a new phase of growth and validation. Over the past year, we made meaningful progress advancing our mission to deliver environmentally sustainable fire inhibitor solutions while laying the foundation for scalable, long-term commercial success. Revenue grew to $2.4 million in 2025, up from $808,000 in 2024, reflecting broader adoption of our products and early-stage commercialization efforts... In December, we achieved a significant corporate milestone with the successful uplisting of CitroTech's common stock to the NYSE American. This transition reflects the progress we have made in strengthening our business, governance and financial profile, while increasing our visibility within the investment community. Our presence on a national exchange positions CitroTech to better access capital markets and support our long-term expansion...We completed a $8.1 million in Series C financing through a combination of preferred equity and convertible instruments, providing capital to accelerate commercialization, expand operations and support early-stage market adoption. Our balance sheet is stronger, and we have the financial flexibility to execute on our strategy and position CitroTech for continued growth... CitroTech continues to set the standard for fire inhibition, and in 2025, we strengthened our position as an industry leader... We continued to invest in the long-term strength of our platform by expanding our intellectual property portfolio. We now hold 37 granted patents and 45 filed or pending applications, covering core chemistry, application methods and fire inhibition technologies... We experienced encouraging adoption of our products by fire departments, particularly across California. At the same time, our wood treatment products advanced toward commercialization for the fire-retardant-treated lumber market... We also continued deploying CitroSafe Systems, proactive wildfire defense solutions for residential and commercial properties... Our focus for 2026 is execution and scale. Revenue growth is expected to accelerate as wildfire season intensifies and commercial channels expand. We are actively building partnerships across the lumber and building materials industry to increase adoption of fire-retardant-treated wood products. Deployment of CitroSafe Systems will expand beyond proof-of-concept, including deeper integration with insurance solutions. To support growth, we anticipate a measured increase in sales and general and administrative expenses as we strengthen supply chains, expand production capabilities and forge strategic partnerships. Innovation remains central, as we advance next-generation formulations and explore new applications for our technology platform. "

CitroTech announced a strategic partnership with All Terrain Fire Support. The collaboration is designed to help federal, state, and military agencies prevent wildfires and safeguard assets using safe, non-toxic, and long-lasting protection. The companies expect the partnership to initially focus on U.S. federal and military opportunities, with the potential to expand across the Western United States over time.

General Enterprise Ventures announced a commercial partnership with a national distributor to produce Class A fire-rated lumber using CitroTech's factory-applied, non-pressure impregnated chemistry. The partnership, which officially commenced December 1, brings three of the lumber company's many facilities online to dip-treat dimensional lumber for commercial distribution, marking one of the first commercial-scale adoptions of non-pressure treated Class A fire-rated lumber in the U.S. The agreement currently covers facilities located in the Western United States and will support homes being built in fire-prone regions, as well as homeowners and architects rebuilding in communities devastated by wildfire. CitroTech anticipates signing additional lumber and building material partners in early 2026 as adoption of the breakthrough treatment accelerates.